BMS-986179 + recombinant human hyaluronidase PH20

**BMS-986179 + recombinant human hyaluronidase PH20** is an investigational combination therapy evaluated for advanced solid tumors. BMS-986179 is a monoclonal antibody targeting CD73, an ectoenzyme involved in adenosine production within the tumor microenvironment. By inhibiting CD73, BMS-986179 may reduce immunosuppressive adenosine signaling, thereby potentially enhancing anti-tumor immune responses. Recombinant human hyaluronidase PH20 facilitates subcutaneous administration of large-volume therapeutics by degrading hyaluronan in tissue, improving drug absorption and distribution. In combination, BMS-986179 may be more effectively delivered, especially subcutaneously, aiding tumor penetration and immunotherapy efficacy. The therapy is primarily being developed and tested by Bristol Myers Squibb, often in combination arms that include rHuPH20[4][6][5].

Other names

BMS-986179BMS986179BMS 986179recombinant human hyaluronidase PH20rHuPH20rHuPH-20rHuPH 20